Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Want to see STRO full AI Analyst Report?
STRO Stock Chart & Stats
$31.55
-$0.05(-2.48%)
At close: 4:00 PM EST
$31.55
-$0.05(-2.48%)
Day’s Range― - ―
52-Week Range$6.73 - $43.85
Previous CloseN/A
Volume326.60K
Average Volume (3M)987.85K
Market Cap
$404.82M
Enterprise Value$188.34M
Total Cash (Recent Filing)$202.56M
Total Debt (Recent Filing)$13.63M
Price to Earnings (P/E)―
Beta3.53
Next Earnings
Aug 10, 2026EPS Estimate
-2.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.49
Shares Outstanding16,570,438
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit1.92
Enterprise Value/Ebitda-1.77
Forecast
1Y Price Target
$48.44Price Target Upside53.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-8.99
Revenue Forecast (FY)$41.37M
Bulls Say, Bears Say
Bulls Say
Proprietary Cell-free PlatformSutro's XpressCF cell-free platform is a durable competitive asset enabling rapid, precise protein engineering. It supports both in-house ADC programs and partner collaborations, creating a structural moat for recurring R&D partnerships, licensing revenues, and faster iteration cycles over multiple years.
Very High Gross MarginsConsistently ~98% gross margins reflect a scalable, asset-light commercial model (collaborations/licensing) where incremental revenues convert to gross profit efficiently. This structural margin advantage can enable operating leverage over time as partner-funded programs and milestones scale.
Extended Runway And Partner ValidationThe $110M raise materially extends cash runway into 2028, reducing near-term solvency pressure, while partner milestone payments and an Astellas program entering the clinic signal external validation. Together these structural funding and partnership elements support multi-year R&D and de-risk program advancement.
Bears Say
Heavy Cash BurnSutro's sustained, large negative operating and free cash flow (~$151-152M TTM) creates structural reliance on external financing to fund clinical development. Persistent burn increases dilution risk over time and constrains the company's ability to self-fund pipeline progression without recurring capital raises.
Negative Stockholders' EquityA negative equity position (~-$66.9M TTM) weakens the balance sheet and reduces financial flexibility. This structural impairment can hinder access to non-dilutive debt, complicate covenant negotiations, and signal solvency risk to partners and counterparties over the medium term.
Lumpy, Volatile Revenue And Deep LossesRevenue volatility (TTM down ~281%) and very large net losses (net margin ~-186%) reflect reliance on lump-sum partner payments and uneven program timing. This structural unpredictability complicates sustainable margin improvement and makes long-term planning and reinvestment more contingent on milestone timing and financings.
Sutro Biopharma News
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $6.73 and its highest was $43.85 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $404.82M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Aug 10, 2026 which is in 68 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on May 14, 2026. The company reported -$2.94 earnings per share for the quarter, missing the consensus estimate of -$2.736 by -$0.204.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -2.17.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 16,570,438 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$2.94 in its last earnings report, missing expectations of -$2.736. Following the earnings report the stock price went up 1.432%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sutro Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.44 (53.55% Upside)
$48.44 (53.55% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.43%
12-Months-Change
Fundamentals
Return on Equity
275.30%
Trailing 12-Months
Asset Growth
-24.72%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
STRO Stock 12 Month Forecast
Average Price Target
$48.44
▲(53.55% Upside)
Technical Analysis
Ownership Overview
0.81% Insiders
10.89% Mutual Funds
59.34% Other Institutional Investors
24.49% Public Companies and
Individual Investors